دورية أكاديمية
Pioglitazone Improvement of Fasting and Postprandial Hyperglycemia in Mexican American Patients with Type 2 Diabetes: A Double Tracer OGTT Study
| العنوان: | Pioglitazone Improvement of Fasting and Postprandial Hyperglycemia in Mexican American Patients with Type 2 Diabetes: A Double Tracer OGTT Study |
|---|---|
| المؤلفون: | Glass, Leonard C, Cusi, Kenneth, Berria, Rachele, Petz, Roberta, Cersosimo, Eugenio, DeFronzo, Ralph A, Gastaldelli, Amalia |
| المساهمون: | Department of Medicine, Diabetes Division, The University of Texas Health Science Center at Houston (UTHealth), Mass Spectrometry-stable isotope lab, Institute of Clinical Physiology |
| المصدر: | ISSN: 0300-0664. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2010 |
| المجموعة: | Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
| مصطلحات موضوعية: | Medicine |
| الوصف: | International audience ; Objectives: By using tracer techniques we explored the metabolic mechanisms by which pioglitazone treatment for 16-weeks improves oral glucose tolerance in patients with type 2 diabetes as compared to subjects without diabetes. Methods: In all subjects, before and after treatment, we measured rates of tissue glucose clearance (MCR), oral glucose appearance (RaO), and endogenous glucose production (EGP) during a (4-hour) double tracer OGTT (1-14C-glucose orally and 3-3H-glucose intravenously). Basal hepatic insulin resistance index (HepIR) was calculated as EGPxFPI. ß-cell function was assessed as the incremental ratio of insulin to glucose (∆I/∆G) during the OGTT. Results: Pioglitazone decreased fasting plasma glucose concentration (10.5 ± 0.7 to 7.8 ± 0.6 mM, p<0.0003) and HbA1c (9.7 ± 0.7 to 7.5 ± 0.5%, p<0.003) despite increased body weight and no change in plasma insulin concentrations. This was determined by a decrease both in fasting EGP (20.0±1.1 to 17.3±0.8 µmol/kgffm•min, p<0.005) and HepIR (from 8194 declined by 49% to 3989, p<0.002). During the OGTT total glucose Ra during the 0-120 min time period following glucose ingestion decreased significantly due to a reduction in EGP. During the 0-240 minute time period pioglitazone caused only a modest increase in MCR (p<0.07) but markedly increased ∆I/∆G (p=0.003). The decrease in 2h-postprandial hyperglycemia correlated closely with the increase in ∆I/∆G (r=-0.76, p=0.004) and tissue clearance (r=-0.74, p=0.006) and with the decrease in HepIR (r=0.62, P=0.006). Conclusions: in diabetic subjects with poor glycemic control pioglitazone improves oral glucose tolerance mainly by enhancing the suppression of EGP and improving ß-cell function. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-00552605; https://hal.archives-ouvertes.fr/hal-00552605Test; https://hal.archives-ouvertes.fr/hal-00552605/documentTest; https://hal.archives-ouvertes.fr/hal-00552605/file/PEER_stage2_10.1111%252Fj.1365-2265.2010.03811.x.pdfTest |
| DOI: | 10.1111/j.1365-2265.2010.03811.x |
| الإتاحة: | https://doi.org/10.1111/j.1365-2265.2010.03811.xTest https://hal.archives-ouvertes.fr/hal-00552605Test https://hal.archives-ouvertes.fr/hal-00552605/documentTest https://hal.archives-ouvertes.fr/hal-00552605/file/PEER_stage2_10.1111%252Fj.1365-2265.2010.03811.x.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.F3B7B452 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/j.1365-2265.2010.03811.x |
|---|